EMBO Gold Medal

OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann

Retrieved on: 
Monday, April 8, 2024
Royal, Medicine, FRS, Biochemical Society, Translational research, Wellcome Sanger Institute, Woman, Drug discovery, Trinity College, Royal Society, International, GSK, University, Membrane, Patient, Doctor of Philosophy, EMBO Gold Medal, University College London, Translation, Architecture, Therapy, Immune system, SAB, The Genetics Society, Molecular biology, Pharmaceutical industry

Oxford, United Kingdom – 8th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Sarah Teichmann PhD, FMedSci, FRS to its Scientific Advisory Board (SAB), effective immediately.

Key Points: 
  • Oxford, United Kingdom – 8th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Sarah Teichmann PhD, FMedSci, FRS to its Scientific Advisory Board (SAB), effective immediately.
  • During this time, she also collaborated with OMass’ co-founder, Professor Dame Carol Robinson, on unraveling the in vivo and in vitro assembly of soluble protein complexes.
  • Ali Jazayeri, Chief Scientific Officer at OMass Therapeutics, commented: “I look forward to working with Sarah.
  • Our previous long-standing collaboration on the assembly of soluble protein complexes demonstrates how her skillset can be complementary to our native mass spectrometry approach and can contribute to further developing our drug discovery platform.”
    Sarah Teichmann, Member of the Scientific Advisory Board of OMass Therapeutics, added: “I am thrilled to be joining OMass Therapeutics’ SAB.

Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize

Retrieved on: 
Thursday, January 25, 2024
EMBO Gold Medal, Professional, Heinz, Max Planck Society, CSO, University Medical Center, I&I, Louis-Jeantet Prize for Medicine, UMG, German, Antiviral Research, Psoriasis, WLA, Animal welfare, Creativity, Inflammation, VHH, Pharmaceutical industry

JERUSALEM, Jan. 25, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I) biological products, congratulates the Company's co-lead scientific research collaborator Professor Dr. Dirk Görlich on being awarded the 2024 Louis-Jeantet Prize.

Key Points: 
  • JERUSALEM, Jan. 25, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I) biological products, congratulates the Company's co-lead scientific research collaborator Professor Dr. Dirk Görlich on being awarded the 2024 Louis-Jeantet Prize.
  • Görlich serves as a director of the Max Planck Institute for Multidisciplinary Sciences (MPI-NAT).
  • According to MPI-NAT, Görlich has received several other scientific awards including the Heinz Maier-Leibnitz Prize, the EMBO Gold Medal, the Alfried Krupp Prize, the WLA Prize 2022, and the Animal Welfare Research Prize of the German Federal Ministry of Food and Agriculture.
  • Amir Reichman, Scinai's CEO, commented, "On behalf of Scinai's team, I offer sincere congratulations to Dirk on being awarded the 2024 Louis-Jeantet Prize.

Dr. Sarah Teichmann FmedCci FRS Joins Transition Bio as Scientific Co-Founder

Retrieved on: 
Wednesday, September 22, 2021
Technology, Biotechnology, Nanotechnology, Health, Pharmaceutical, Oncology, Other Science, Research, Software, General Health, Genetics, Science, Data Management, Clinical Trials, Biophysics, Biochemical Society, Distinguished Fellow of the British Computer Society, Artificial intelligence, Research, Computational biology, Wellcome Sanger Institute, Harvard University, OC, EMBO, Medicine, Teichmann, Therapy, Health, Yusuf Hamied Department of Chemistry, Mallinckrodt, Map, Research fellow, Cavendish Laboratory, Physical chemistry, Academy of Medical Sciences (United Kingdom), Laboratory, Gold medal, Fellow, International Society, Biology, Drug design, Genomics, University, Royal Society, Company, EMBO Gold Medal, Disease, Technology, Algorithm, Science, FRCP, Applied physics, Royal, Churchill College, Cambridge, Drug discovery, Transition, Department, FRS, FRSC, Machine learning, Physics, Academy, Management, Pharmaceutical industry

Transition Bio, Inc., (the Company) announced today that Dr. Sarah Teichmann FmedSci FRS, has joined the Company as a Scientific Co-Founder.

Key Points: 
  • Transition Bio, Inc., (the Company) announced today that Dr. Sarah Teichmann FmedSci FRS, has joined the Company as a Scientific Co-Founder.
  • Dr. Samuel Cohen, a former research fellow in Biophysical Chemistry at the University of Cambridge and visiting fellow at Harvard University, is also a Founder of the Company.
  • Martin commented further, From a scientific leadership and breakthrough innovation standpoint, the combination of our scientific team of doctors Weitz, Knowles, Hyslop, and now Teichmann is as good as it could possibly get.
  • Transition Bio is developing one-of-a-kind technologies for biomolecular condensate analysis.